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العالج بعقار الريتوكسيماب يف الوهن العضلي الشديد
تقرير عن طفلني مصابني
رو�شان كول، اآمنة الفطي�شي، رنا عبد الرحيم، رينجيث ماين، رمي عبدواين، عبداهلل العا�شمي
abstract: Myasthaenia gravis (MG) is an autoimmune disease involving the postsynaptic receptors in the 
neuromuscular junction. The condition is characterised by fatigable weakness of the skeletal muscles and is uncommon 
in children. Acetylcholinesterase inhibitors and immune-modifying medications are usually considered the mainstay 
of treatment. However, these medications have to be given on a lifelong basis so that patients remain in remission; 
furthermore, drug-related side-effects can have a major impact on quality of life. We report two paediatric cases who 
were treated for MG at the Sultan Qaboos University Hospital, Muscat, Oman, in 2007 and 2008, respectively. Rituximab 
was eventually administered to each patient after their condition failed to improve despite several years of standard 
treatment with acetylcholinesterase inhibitors and immune-modifying medications. Overall, rituximab resulted in 
complete remission in one case and significant clinical improvement in the other case.
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الع�شلية.  الع�شبية  الو�شلة  امل�شبك يف  بعد  التي ت�شيب م�شتقبالت ما  الذاتية  املناعة  اأمرا�ض  اأحد  ال�شديد هو  الع�شلي  الوهن  امللخ�ص: 
اأ�شتيل والأدوية املعدلة للمناعة  الهيكلية وهوغري �شائع يف الأطفال. وعادة ما تعترب مثبطات  الع�شالت  تتميز احلالة ب�شعف جهد يف 
الدعامة الأ�شا�شية للعالج. ومع ذلك ، يجب اإعطاء هذه الأدوية على مدى احلياة حتى يظل املر�ض يف حالة �شكون. عالوة على ذلك ، ميكن 
اأن يكون لها تاأثري كبري على جودة احلياة. هذا تقرير عن حالتني لالأطفال م�شابني مبر�ض الوهن  لالآثار اجلانبية املرتبطة بالعقاقري 
الع�شلي ال�شديد ومت عالجهم يف م�شت�شفى جامعة ال�شلطان قابو�ض، م�شقط، عمان، يف عام 2007 و 2008. ويف وقت لحق، اأعطي عقار 
اأدى  اإىل كلتا املراهقني مل ي�شتجيبا للعالج مبثبطات املناعة ومثبطات الأ�شيتيل كولين�شرتيز لعدة �شنوات. وعموما فقد  الريتوك�شيماب 
الريتوك�شيماب ايل �شكون كامل يف احلالة الأوىل والتح�شن ال�رضيري الكبري يف احلالة الثانية.
الكلمات املفتاحية: الوهن الع�شلي ال�شديد؛ ريتوك�شيماب؛ الأطفال؛ امل�شتقبالت الكولينية؛ تقرير حالة؛ عمان.
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A seven-year-old female patient presented to SQUH in 
2007 and was diagnosed with MG. She was prescribed 
prednisolone, pyridostigmine and azathioprine and 
underwent a thymectomy in 2009. Her acetylcholine 
receptor (AchR) antibody levels were 85,000 nmol/L 
in 2007 and 292 nmol/L in 2013 (normal range: 
0–0.25 nmol/L). An anti-muscle-specific kinase (MuSK) 
antibody test was not performed. For several years, 
she continued taking pyridostigmine, prednisolone 
and azathioprine; however, she still had minimal ptosis 
and was easily fatigued. She could not participate in 
active games and, according to the Myasthenia Gravis 
Foundation of America (MGFA) scale, her muscular 
weakness was categorised as class IVa.8 The patient 
was the elder sister of another previously reported 
female child with MG.9
In 2012, five years after her initial MG diagnosis, 
the patient was prescribed rituximab. Although she 
Myasthaenia gravis (mg) is an auto-immune neuromuscular disease often pres- enting as generalised weakness.1 The cond-
ition is most often seen in the adult population; in 
a previously reported series of MG patients from 
Oman, only 10% were children.2 Acetylcholinesterase 
inhibitors and immune-modifying medications such 
as steroids, mycophenolate, azathioprine, intravenous 
immunoglobulins (IVIGs) and plasmapheresis are 
considered the mainstay of treatment for MG; however, 
these treatments must be maintained over the course 
of the patient’s life.1 In addition, thymectomies are 
reported to be effective for a large number of patients.1,3 
Recently, various reports have shown remarkable 
improvements in MG cases following treatment with 
rituximab.4–7 This case report describes two children 
with severe MG who were refractory to conventional 
treatment. Both children responded well to rituximab 
therapy, resulting in marked improvement in one case 
and complete remission in the second case.
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demonstrated significant clinical improvement, it 
was necessary to continue treatment with the other 
drugs. At the time of writing, she was taking 50 mg 
of azathioprine twice a day, 30 mg of pyridostigmine 
three times a day and 5 mg of prednisolone once a day. 
Her cluster of differentiation (CD)19 count remained 
below 0.1 x 109/L (normal range: 0.2–0.5 x 109/L) for 
almost five years.
Case Two
A five-year old girl presented to SQUH in 2008 with 
ptosis, difficulty swallowing and mild generalised 
weakness. Clinical investigations confirmed a diagnosis 
of MG. The results of AchR antibody tests performed 
in 2008 and 2013 were negative. An anti-MuSK anti-
body test was not performed. She was prescribed 
pyridostigmine, 2 mg/kg/day of prednisolone, azathio- 
prine and atenolol (due to steroid-related hyper-
tension). She also developed severe Cushingoid 
features and osteopaenia with reduced bone density 
requiring vitamin D therapy. She was on regular 
monthly IVIG therapy (1 g/kg). A thymectomy was 
advised but not performed, as her father did not 
consent to the procedure. According to the MGFA 
scale, her muscular weakness was categorised as 
class IVb.8
As the patient’s symptoms did not improve, 
rituximab treatment was initiated in 2014, more than 
five years after her initial MG diagnosis. Clinical 
improvement was evident after the second dose. 
After three months, once all four doses of rituximab 
had been administered, prednisolone was tapered off 
and all other drugs were discontinued, including the 
azathioprine, pyridostigmine and atenolol. At the time 
of writing, the patient had been asymptomatic for two 
years. She was given one additional dose of rituximab 
in 2016 after her CD19 count had normalised. 
A summary of the clinical characteristics and 
management plans of both cases is shown in Table 1. 
Discussion
Rituximab is an anti B-cell CD20 monoclonal 
antibody used in the treatment of several autoimmune 
neurological disorders, including neuromyelitis optica, 
opsoclonus ataxia syndrome and autoimmune neuro-
pathies.10,11 The drug was first used for the treatment 
of MG in 2003.12 Since then, several reports have 
been published indicating a good clinical response to 
the drug.4,5,13–15 In a recent systematic review, Tandan 
et al. reported that 71% of MG patients have shown 
improvement with rituximab therapy.6 Currently, 
a multi-centre phase II rituximab trial is being 
undertaken among MG patients in the USA, with 
preliminary results to be reported soon.16 In a 10-
year open-label study, rituximab was well-tolerated, 
resulting in sustained clinical improvement and the 
eventual tapering off of other immune therapies.7
Although the majority of MG cases demonstrate 
an effective and sustained response with rituximab 
with few complications, the potential adverse effects 
of the drug should be considered prior to treatment.7,9 
Rituximab can cause serious side-effects, including 
progressive multifocal leukoencephalopathy, the react-
ivation of dormant hepatitis and epidermal necro- 
lysis.5,10,11 However, as the current cases were asympt-
omatic, they were not screened for these side-effects.
In the first case, the patient was the elder sister of 
another previously reported female child with class V 
MG who presented to SQUH in 2012 at the age of four 
years.9 The younger sister was prescribed incremental 
doses of prednisolone and pyridostigmine, but her 
Table 1: Clinical characteristics and management plans 
of two paediatric cases of myasthaenia gravis treated 
with rituximab
Case one Case two







MG severity* IVa IVb
Initial 
treatment
PRD, PYD, IVIGs 
and AZA
PRD, PYD, IVIGs, 






AchRab status Positive† Negative
Rituximab 
dosage
Four doses of 375 
mg/m2




After the fourth 
dose








PRD, PYD and 
AZA
None
Outcome Significant clinical 
improvement
In remission
MG = myasthenia gravis; PRD = prednisolone; PYD = pyridostigmine; 
IVIGs = intravenous immunoglobulins; AZA = azathioprine; 
AchRab = acetylcholine receptor antibody.
*According to the Myasthenia Gravis Foundation of America scale.8
†Initially, her AchRab levels were 85,000 nmol/L in 2007 before 
dropping to 292 nmol/L in 2013.
Roshan Koul, Amna Al-Futaisi, Rana Abdelrahim, Renjith Mani, Reem Abdwani and Abdullah Al-Asmi
Case Report | e225
condition progressively worsened over time and she 
was intubated six times.9 Nine months later, rituximab 
treatment was initiated at weekly intervals, as per 
standard SQUH protocols [Table 2]. Three days 
after the first dose, her ventilatory parameters began 
to improve, with all baseline symptoms of weak- 
ness resolving after the fourth dose.9 After 14 months, 
her CD19 count normalised and she remained asymp-
tomatic for 20 months; however, she subsequently 
relapsed and underwent a second cycle of rituximab 
in 2013.9 Her CD19 count normalised again in 2016 
and she was given another single dose of rituximab. 
The patient remained asymptomatic, with no clinical 
evidence of any further relapse.9 Rituximab was thus 
administered to the first case in light of the successful 
outcome achieved for her younger sister.
At present, there are no indicators other than 
CD19 count to guide rituximab use following the 
first round of treatment. Although the CD19 count 
is initially suppressed by rituximab, it normalises once 
the effect of the drug wears off.13 Rituximab treatment 
should therefore be repeated once the CD19 count 
normalises to avoid clinical relapse.17 In the second 
case, the rituximab dose was repeated once the 
patient’s CD19 count had normalised, before the 
recurrence of any clinical weakness. For the first case, 
Table 2: Standard protocols for paediatric rituximab treatment at the Sultan Qaboos University Hospital, Muscat, Oman
Protocol
Dosage • 375 mg/m2 once weekly for four weeks, with subsequent doses depending on the patient’s initial response to 
treatment.
Dilution • Add a solution of 0.9% sodium chloride or 5% glucose for a final concentration of 1–4 mg/mL.
• Mix gently to avoid foaming.
Pre-treatment • The following medications should be administered orally 30–60 minutes prior to each infusion: 
   a) 15 mg/kg of paracetamol (up to a maximum of 1 g) 
   b) Chlorpheniramine at dosages of: 
       (i) 1 mg twice for patients between 1 month and 2 years old 
       (ii) 1 mg every four to six hours for patients between 2–6 years old 
       (iii) 2 mg every four to six hours for patients between 6–12 years old 
       (iv) 4 mg every four to six hours for patients between 12–18 years old.
• Intravenous corticosteroids may also be given if required (e.g. two doses of 0.1 mg/kg of dexamethasone).
• Consider withholding antihypertensive medications for 24 hours to prevent hypotension.
• Screen for hepatitis B before starting rituximab, as this treatment can reactivate dormant infections.
• For patients with pre-existing pulmonary disease, concomitant nebulised salbutamol should be considered.
Administration • The drug should be infused over an 8-hour period at an initial rate of 10 mL/hour, before increasing to 15 mL/hour, 
20 mL/hour, 30 mL/hour and 40 mL/hour for half-hour intervals each. The infusion rate should then be maintained 
at 50 mL/hour until the entire dose has been administered. 
Compatibility • Apart from 0.9% sodium chloride and 5% glucose, rituximab should not be mixed with any other fluids or drugs.
• The catheter should be flushed with saline or glucose before and after the rituximab infusion.
Potential adverse 
effects
• Fever and chills/rigors may occur in up to 50% of patients.
• Infusion-related symptoms include nausea, vomiting, urticaria, headaches, bronchospasms, dyspnoea, angioedema 
and hypotension.
• Severe gastrointestinal adverse effects including obstruction and perforation have been reported; complaints of 
abdominal pain, especially early in the treatment course, should be investigated.
• Patients with pre-existing pulmonary disease may be at greater risk of respiratory adverse effects.
• Rituximab can exacerbate or induce arrhythmias or angina.
• Adverse reactions are usually more severe during the first infusion; however, anaphylaxis can occur at any time and 
at any stage of treatment.
• In case of anaphylaxis, emergency treatment (i.e. adrenaline and corticosteroids) should be readily available.
Observation and 
monitoring
• The patient’s vital signs and the site of the infusion should be checked every 15 minutes during the first hour of the 
infusion, then every hour until the infusion is complete.
• Routine observation should continue at 30-minute intervals for two hours following the completion of the infusion 
in order to monitor any delayed reactions.
• The infusion should be halted immediately if any adverse effects arise; if the effects are mild and the symptoms 
resolve, the infusion may be restarted at half the previous rate of infusion.
• Cardiac monitoring may be required for patients with cardiac dysfunction.
• Continue to monitor patients for signs of hepatitis B infection during and for several months after treatment; 
rituximab must be discontinued if fulminant hepatitis develops.
Follow-up • A complete blood count, including differential and platelet counts, should be obtained at weekly intervals for 
inpatients and fortnightly intervals for outpatients.
• Lymphocyte subset panels should be undertaken every three months.
• Urea and electrolyte levels should be monitored on a daily basis for inpatients and prior to every infusion for 
outpatients.
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the CD19 count remained suppressed and had still not 
reached normal values more than four years after the 
initial rituximab treatment. The duration of the period 
of CD19 suppression is variable.13 In this case, the 
patient was asymptomatic and hence was not screened 
for progressive multifocal leukoencephalopathy or a 
John Cunningham virus infection.
Tandan et al. noted that rituximab resulted in 
a better response among patients with anti-MuSK 
antibodies compared to those with anti-AchR anti-
bodies.6 In the current report, the second patient was 
negative for AchR antibodies and seemed to respond 
most positively to the rituximab treatment. The 
first patient had positive AchR antibody test results, 
which, despite a significant decline between 2007 and 
2013, never normalised; furthermore, this patient 
did not respond as well to rituximab treatment as 
the AchR antibody-negative patient. Negative AchR 
antibody test results may therefore be a good marker 
for predicting remission with rituximab treatment. 
However, it is important to note that AchR antibody 
levels appear to increase with age and that cases of 
childhood-onset MG may initially appear to be AchR 
antibody-negative.17 
It is not yet clear whether there is any correlation 
between the duration of MG and the efficacy of ritu-
ximab therapy. In the first case, rituximab did not 
appear to result in the complete resolution of MG 
symptoms, although the therapy was not initiated until 
five years after her initial MG diagnosis. Rituximab 
treatment was also far more effective for her younger 
sister when administered within a year of the onset of 
the symptoms.9 However, the second case also received 
rituximab after having had MG for five years, resulting 
in the complete amelioration of her MG symptoms. 
Future studies may therefore reveal more information 
in this context. 
A thymectomy is often performed as part of MG 
treatment for adults; however, while it is sometimes 
used in childhood MG as well, the effect of the 
procedure is slow and takes place over time.1,3 In the 
first case, the patient had undergone a thymectomy 
seven years prior to rituximab treatment, with 
seemingly little improvement. As such, the authors 
suggest that rituximab therapy be considered for 
paediatric patients with MG from the time of onset 
of clinical symptoms, except in cases of ocular MG. 
However, local experience using rituximab is advised. 
Additionally, the long-term outcomes of rituximab 
in MG patients with primary disease is unknown. 
Therefore, the long-term follow-up of such patients is 
recommended to ensure sustained remission and to 
monitor for possible side-effects.
Conclusion
This report describes two cases of paediatric MG 
in which the use of rituximab therapy resulted 
in remission or significant clinical improvement. 
Rituximab should therefore be considered in similar 
cases from the time of disease onset. However, the 
authors highly recommend the continuous follow-
up of these patients as the long-term outcome of this 
treatment has not yet been established. 
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